NIKKEI 225
38,882.64 +496.91 (+1.29%) HANG SENG
19,432.73 +359.02 (+1.88%) CRUDE OIL
79.02 +0.39 (+0.50%) GOLD FUTURES
2,395.00 +0.10 (+0.00%) DOW
39,908.00 +349.89 (+0.88%) Bitcoin GBP
51,827.76 +2,989.66 (+6.12%)
INNOVENT BIOLOGICS INC. (6IB.DU)
- PR Newswire
Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical trial (DREAMS-2) of mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese subjects with type 2 diabetes (T2
- PR Newswire
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as Monotherapy for Advanced Gastric Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI343 as monotherapy for the treatment of claudin18.2-pos
- PR Newswire
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announces the appointment of Dr. Samuel Zhang as its Global Chief Business Officer (CBO). In this role, Dr. Zhang will be responsible for Innovent's global strategy and business development, and his reporting line is Dr.
